1,023,130 Shares in Ventyx Biosciences, Inc. $VTYX Purchased by Baker BROS. Advisors LP

Baker BROS. Advisors LP bought a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the third quarter, Holdings Channel.com reports. The institutional investor bought 1,023,130 shares of the company’s stock, valued at approximately $3,182,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Boothbay Fund Management LLC boosted its position in shares of Ventyx Biosciences by 54.2% during the 3rd quarter. Boothbay Fund Management LLC now owns 432,527 shares of the company’s stock valued at $1,345,000 after acquiring an additional 152,114 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Ventyx Biosciences in the third quarter worth approximately $666,000. Man Group plc bought a new position in shares of Ventyx Biosciences in the third quarter worth approximately $251,000. Two Sigma Investments LP purchased a new stake in Ventyx Biosciences in the third quarter valued at approximately $1,356,000. Finally, Bridgeway Capital Management LLC raised its stake in Ventyx Biosciences by 335.8% in the third quarter. Bridgeway Capital Management LLC now owns 233,600 shares of the company’s stock valued at $726,000 after purchasing an additional 180,000 shares in the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on VTYX. Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a research note on Thursday, January 8th. UBS Group restated a “neutral” rating and set a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Lifesci Capital reaffirmed a “market perform” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a report on Thursday, January 8th. Piper Sandler lowered shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price for the company. in a research report on Thursday, January 8th. Finally, Canaccord Genuity Group cut Ventyx Biosciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $16.00 to $14.00 in a research note on Thursday, January 8th. Eight analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $14.00.

Ventyx Biosciences Price Performance

NASDAQ:VTYX opened at $14.00 on Friday. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -9.33 and a beta of 1.26. The business has a 50 day moving average of $13.74 and a 200 day moving average of $8.85. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $25.00.

Insider Activity at Ventyx Biosciences

In related news, insider John Nuss sold 12,675 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. The trade was a 1.96% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 14.49% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.